New Directions in Small Molecule Drug Discovery
joint with Computer-Aided Drug Design
Organizer(s): William J. Greenlee, George Hartman and Anna K. MappDate: April 20 - 25, 2010
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
The purpose of this meeting is to highlight exciting new opportunities in the discovery of small molecule drug candidates, including the following: • Novel targets for small molecules, including disruption of protein-protein interactions, allosteric modulation of receptors and enzymes, and direct interactions with transcription factors. • Enabling technologies for the discovery of new small molecule leads, including diversity-oriented screening, fragment screening, and affinity screening. • The most successful structure-based design approaches to the optimization of leads. A focus of the conference will be successful applications structure-based design in the discovery of therapeutics for the treatment of HCV infection (protease inhibitors) and cancer (protein kinase inhibitors). A session comprising first-time disclosures of Phase 2 clinical candidates will illustrate successful applications of structure-based design in drug discovery.
Scholarship Deadline: December 20 2009
Discounted Abstract Deadline: December 21 2009
Abstract Deadline: January 20 2010
Discounted Registration Deadline: February 23 2010
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Bristol-Myers Squibb Company
Heptares Therapeutics Ltd
Merck & Co., Inc.
Merck Research Laboratories
Schering-Plough Research Institute
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: